Investment
Features
FeesSafety
Academy
More
Pluang+

Compare GE Vernova Inc (GEV) vs Vaxcyte Inc. Common Stock (PCVX) Price & Performance

GE Vernova IncTrade
Vaxcyte Inc. Common StockTrade

Price performance (Past 24H)

Key statistics

GE Vernova Inc vs Vaxcyte Inc. Common Stock — how do they compare? GE Vernova Inc trades at $925.26 (market cap $267.41B), while Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B). The key difference: GE Vernova Inc is far larger — about 25.4× Vaxcyte Inc. Common Stock's market cap, and GE Vernova Inc pays a 0.2% dividend while Vaxcyte Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold GE Vernova Inc for 37 Days and Vaxcyte Inc. Common Stock for 0 Days on average.

GEVPCVX
Market Cap
$267.41B$10.51B
Volume
1,900,0742,644,694
Sector
IndustrialsHealth
52-Week High
$1.17K$73.82
52-Week Low
$547.96$40.32
Typical Hold Time
37 Days0 Days
Enterprise Value
$257.08B$9.14B
Dividend Yield
0.2%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

GE Vernova Inc

GE Vernova (GEV) trades at $1,004.04, up 0.73% with strong bullish momentum from technical indicators and positive analyst sentiment. The stock shows impressive fundamental performance with 2026 revenue projected at $41.4B and net income of $9.5B, representing a 23.03% profit margin. Recent catalysts include securing the first US construction permit for its BWRX-300 small modular reactor and strong backlog growth to $176B, positioning the company to benefit from AI-driven power demand.

The outlook remains positive with 76% analyst buy ratings and a $1,270 consensus price target suggesting 26% upside potential. Key risks include valuation concerns with P/E of 28.79 and EV/EBITDA of 85.64 appearing elevated, along with execution challenges in the wind power segment. The stock's strong cash flow generation and positioning in the AI power infrastructure theme support continued growth prospects despite rich valuations.

Vaxcyte Inc. Common Stock

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

GEV
21% Buy79% Sell
Avg holding period · 37 Days
PCVX
100% Buy0% Sell
Avg holding period · 0 Days

About GE Vernova Inc

GE Vernova is a global leader in the electric power industry. It provides sustainable energy solutions across gas, wind, and hydro sectors, focusing on modernizing the world's power grids.

Read more on GEV →

About Vaxcyte Inc. Common Stock

Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.

Read more on PCVX →